EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Polypharmacy in HIV : Rethinking what counts and why it matters

Luxsena Sukumaran iD, Alan Winston, Catia Marzolini iD, Saye Khoo, Marta Boffito, Nadia Naous, Caroline A Sabin iD

HIV Medicine · 2026-02 · 27 (2) · 186-199

DOI: 10.1111/hiv.70129 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift HIV Medicine, online erschienen am 21.10.2025. Verfasst von Luxsena Sukumaran und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Global Health, University College London, London, UK. Hauptthemen laut MEDLINE: Polypharmacy, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polypharmacy, the concurrent use of multiple medications, presents a growing challenge in HIV care as people living with HIV age and experience earlier onset of age‐related co‐morbidities. However, how polypharmacy is defined and assessed in HIV research remains inconsistent. The commonly used threshold of five or more medications, often derived from geriatric medicine, may not adequately reflect the clinical complexity of HIV care, where lifelong antiretroviral therapy (ART) forms the foundation of treatment. This review examines how polypharmacy has been defined and operationalized in HIV studies and compares this to approaches in geriatric research, where tools (e.g., STOPP/START and the Beers criteria) have been more systematically applied. We argue that HIV care can benefit from, but must also adapt, these frameworks to address the unique pharmacologic, psychosocial and adherence‐related considerations faced by people with HIV. We also review emerging evidence linking polypharmacy in HIV with negative outcomes, including increased risk of drug–drug interactions, hospitalization, reduced quality of life, and associated healthcare costs. At the same time, polypharmacy is not inherently inappropriate, as many regimens may reflect guideline‐concordant care. Rather than focusing on medication count alone, attention should shift toward evaluating appropriateness, safety and alignment with the individual's evolving health needs. Finally, we explore the role of deprescribing in HIV care, acknowledging both its promise and the challenges it presents, particularly in preserving ART stability and supporting shared decision‐making. Reframing polypharmacy through an HIV‐specific lens can support safer prescribing and improve outcomes as the HIV population continues to age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PolypharmacyHIV InfectionsAnti-HIV AgentsHumansDrug InteractionsQuality of Life

Stichwörter der Autor:innen

HIVdeprescribingmedication burdenpolypharmacyreview

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Institute for Global Health, University College London, London, UK.
  • National Institute for Health and Care Research (NIHR) Health Protection Research Unit (HPRU) in Blood-borne and Sexually Transmitted Infections at University College London, London, UK.
  • Department of Infectious Disease, Imperial College London, London, UK.
  • Service of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.
  • Division of Infectious Diseases, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Centre for Experimental Therapeutics, University of Liverpool, Liverpool, UK.

ORCID-Profile: Luxsena Sukumaran, Catia Marzolini, Caroline A Sabin

Zitieren

APA

Sukumaran, L., Winston, A., Marzolini, C., Khoo, S., Boffito, M., Naous, N., & Sabin, C. A. (2026). Polypharmacy in HIV : Rethinking what counts and why it matters. HIV Medicine, 27(2), 186-199. https://doi.org/10.1111/hiv.70129

Vancouver

Sukumaran L, Winston A, Marzolini C, Khoo S, Boffito M, Naous N, et al. Polypharmacy in HIV : Rethinking what counts and why it matters. HIV Medicine. 2026;27(2):186-199. doi:10.1111/hiv.70129

BibTeX
@article{Sukumaran2026,
  author = {Sukumaran, Luxsena and Winston, Alan and Marzolini, Catia and Khoo, Saye and Boffito, Marta and Naous, Nadia and Sabin, Caroline A},
  title = {Polypharmacy in HIV : Rethinking what counts and why it matters},
  journal = {HIV Medicine},
  year = {2026},
  volume = {27},
  number = {2},
  pages = {186--199},
  doi = {10.1111/hiv.70129}
}
Kostenlos starten →